🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

445 results for “SK” Clear

  1. Cagrilintide

    Novo Nordisk A/S

    Overweight

    phase 3 small molecule completed

    1 trial

  2. Cannabidiol (CBD)

    Jazz Pharmaceuticals Ireland Limited

    Clinical High Risk for Psychosis (CHR)

    phase 3 small molecule active

    1 trial

  3. Casodex® 50 mg Film-coated Tablets, ANANDRON 150 mg, comprimé, Flutamide 250 mg Tablets, Xtandi - 40 mg soft capsules

    Ningbo Cancer Hospital

    Localised prostate cancer at high risk of recurrence

    phase 3 small molecule active

    1 trial

  4. Concizumab

    Novo Nordisk A/S

    Haemophilia A Without Inhibitors

    phase 3 small molecule active

    1 trial

  5. Concizumab

    Novo Nordisk A/S

    Haemophilia A With Inhibitors

    phase 3 small molecule active

    1 trial

  6. Crystalline cellulose simple occlusive dressing

    The First People's Hospital of Lianyungang

    Split-thickness Skin Graft Donor Sites

    phase 3 other completed

    1 trial

  7. Cyclophosphamide Injection 500 mg., Vincristine Sulfate 1 mg/ml solution for injection, Cisplatin 1 mg/ml concentrate for solution for infusion, Temodal 100 mg hard capsules, Etoposide 20 mg/ml Concentrate for Solution for Infusion, Thiotepa 15 mg Powder for solution for injection , Qarziba 4.5 mg/mL concentrate for solution for infusion, Melphalan 50 mg concentrate and solvent for solution for injection/infusion, Busulfan 6 mg/ml concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution

    The George Institute

    Patients with High Risk Neuroblastoma

    phase 3 small molecule active

    1 trial

  8. DAUNORUBICIN HYDROCHLORIDE, FLUDARABINE, MYLOTARG 5 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, TREOSULFAN, CYTARABINE, BUSULFAN

    Fondazione Telethon ETS

    Favorable-intermediate-risk Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  9. DEGARELIX, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, DEGARELIX, DEGARELIX, TRIPTORELIN , DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN

    Ningbo Cancer Hospital

    very high risk localized or locally advanced prostate cancer

    phase 3 small molecule active

    1 trial

  10. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion.

    Daiichi Sankyo

    High-Risk HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  11. DUOFAG, Chlorid sodný B. Braun 0,9 % infuzní roztok

    Lacuna Pharma Pty Ltd

    Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.

    phase 3 small molecule active

    1 trial

  12. Darleukin, Fibromun

    Philogen S.p.A.

    Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions

    phase 3 small molecule active

    1 trial

  13. Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Cream (Test) vs. Lotricomb® Cream (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin

    Alphapharm Pty Ltd

    moderate to severely inflamed candidiasis of the skin

    phase 3 other active

    1 trial

  14. ELIGARD 45 mg, poudre et solvant pour solution injectable

    Ningbo Cancer Hospital

    Prostatic adenocarnicoma with high risk of recurrence

    phase 3 small molecule active

    1 trial

  15. Esketamine

    Janssen Cilag International NV

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial

  16. Exoskeletal assisted walking

    United Therapeutics Europe Ltd

    Spinal Cord Injuries

    phase 3 other active

    1 trial

  17. FIBRINOGEN, HUMAN, RIVAROXABAN , APIXABAN , ETAMSYLATE , TRANEXAMIC ACID , -, PROTAMINE , -, ERYTHROCYTES , AMINOMETHYLBENZOIC ACID , -, AMINOCAPROIC ACID , Ondexxya 200 mg powder for solution for infusion, EDOXABAN , -

    AstraZeneca AB

    Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

    phase 3 small molecule active

    1 trial

  18. FLUDARABINE PHOSPHATE, DAUNORUBICIN HYDROCHLORIDE, BUSULFAN, Azacitidine Accord 25 mg/mL powder for suspension for injection, CYTARABINE, THIOTEPA

    Fondazione Telethon ETS

    Higher-risk-myelodysplastic syndromes

    phase 3 small molecule active

    1 trial

  19. Faster-acting insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  20. Flucelvax Tetra - suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció e

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  21. GEMCITABINE , JNJ-17000139, MITOMYCIN

    Janssen-Cilag International N.V.

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  22. GSK 2132231A

    GlaxoSmithKline

    Melanoma

    phase 3 small molecule terminated

    1 trial

  23. GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  24. GSK1605786A

    GlaxoSmithKline

    Crohn's Disease

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources